![Eric Venker](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Eric Venker
Directeur Général chez
IMMUNOVANT, INC.
Fortune : 57 M $ au 31/05/2026
Profil
Actuellement, Eric Venker est coprésident et directeur d'exploitation de Roivant Sciences Ltd, président et directeur d'exploitation de Roivant Sciences, Inc. et coprésident et directeur d'exploitation de Roivant Sciences GmbH (toutes deux filiales de Roivant Sciences Ltd) et coprésident et directeur d'exploitation de Montes Archimedes Acquisition Corp. Eric Venker siège également au conseil d'administration d'Arbutus Biopharma Corp, de Sio Gene Therapies, Inc, d'Aruvant Sciences, Inc et d'Immunovant, Inc. Il a précédemment occupé le poste de président du conseil de la qualité du personnel au Columbia University Medical Center. Eric Venker est titulaire d'un doctorat de la Yale School of Medicine et d'un doctorat du St. Louis College of Pharmacy.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ROIVANT SCIENCES LTD. 0,22 % | 24/06/2026 | 1 613 063 ( 0,22 % ) | 48 M $ | 31/05/2026 |
IMMUNOVANT INC 0,13 % | 02/07/2026 | 254 280 ( 0,13 % ) | 8 M $ | 31/05/2026 |
Postes actifs de Eric Venker
| Sociétés | Poste | Début |
|---|---|---|
| IMMUNOVANT, INC. | Directeur Général | 21/04/2025 |
| ROIVANT SCIENCES LTD. | President | 01/01/2021 |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | President | 01/01/2021 |
Aruvant Sciences, Inc.
 Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning | Directeur/Membre du Conseil | - |
Roivant Sciences GmbH
 Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Develops and markets biopharmaceutical products | President | 01/01/2018 |
Roivant Social Ventures, Inc.
 Roivant Social Ventures, Inc. Roivant Social Ventures, Inc. is a not-for-profit social impact organization dedicated to advancing health equity by applying private sector strategies to biopharma innovation and healthcare delivery. The private company is based in New York, NY. The company focuses on ensuring equitable access to medicines and medical care regardless of geography, wealth, or insurance status by investing in early-stage companies developing therapies for underserved patient populations, incubating healthcare-focused social entrepreneurs, and embedding drug development education in academic institutions through fellowships and internships to promote diversity in the biopharma industry and clinical trials. Roivant Social Ventures also partners with companies, institutes, and organizations to create systemic improvements in healthcare access and delivery, with key focus areas including gene therapy access, increasing diversity in clinical trials, and fostering diversity, equity, and inclusion opportunities for future biopharma leaders. Lindsay Androski has been the CEO of the company since 2016. | Directeur/Membre du Conseil | 01/01/2014 |
Anciens postes connus de Eric Venker
| Sociétés | Poste | Fin |
|---|---|---|
| SIO GENE THERAPIES INC. | Directeur/Membre du Conseil | 05/04/2023 |
| ARBUTUS BIOPHARMA CORPORATION | Directeur/Membre du Conseil | 25/05/2022 |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Directeur Général | 01/01/2015 |
| ░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░ | - |
| ░░░░░░░░ ░░░░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Eric Venker
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
19
Relations au 1er degré
12
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 12 |
|---|---|
Arbutus Biopharma Corp.
 Arbutus Biopharma Corp. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics which targets viral diseases | Health Technology |
Roivant Sciences Ltd.
 Roivant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a holding company through its subsidiaries develops restorative therapies for autoimmune diseases | Health Technology |
St. Louis College of Pharmacy
 St. Louis College of Pharmacy Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Columbia University Medical Center
 Columbia University Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale School of Medicine
 Yale School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roivant Sciences GmbH
Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Develops and markets biopharmaceutical products | Health Technology |
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops gene therapies to treat neurodegenerative diseases | Health Technology |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Health Technology |
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning | Health Technology |
Immunovant, Inc.
 Immunovant, Inc. BiotechnologyHealth Technology Develops restorative therapies for autoimmune diseases | Health Technology |
Montes Archimedes Acquisition Corp.
 Montes Archimedes Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Roivant Social Ventures, Inc.
Roivant Social Ventures, Inc. Roivant Social Ventures, Inc. is a not-for-profit social impact organization dedicated to advancing health equity by applying private sector strategies to biopharma innovation and healthcare delivery. The private company is based in New York, NY. The company focuses on ensuring equitable access to medicines and medical care regardless of geography, wealth, or insurance status by investing in early-stage companies developing therapies for underserved patient populations, incubating healthcare-focused social entrepreneurs, and embedding drug development education in academic institutions through fellowships and internships to promote diversity in the biopharma industry and clinical trials. Roivant Social Ventures also partners with companies, institutes, and organizations to create systemic improvements in healthcare access and delivery, with key focus areas including gene therapy access, increasing diversity in clinical trials, and fostering diversity, equity, and inclusion opportunities for future biopharma leaders. Lindsay Androski has been the CEO of the company since 2016. |
Choisissez Zonebourse 
